CD14+CD16-Low Monocyte Subset Predicts Non-Progressive HIV Disease: Evidence of a New Prognostic and Diagnostic Biomarker

Biomarkers and Applications
doi 10.29011/2576-9588.100028
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Gavin Publishers

Related search

The CD14+CD16+ Inflammatory Monocyte Subset Displays Increased Mitochondrial Activity and Effector Function During Acute Plasmodium Vivax Malaria

PLoS Pathogens
ImmunologyMolecular BiologyVirologyMicrobiologyParasitologyGenetics
2014English

Clinical Immunology Gastric Cancer Increase the Percentage of Intermediate (CD14++CD16+) and Nonclassical (CD14+CD16+) Monocytes

Central-European Journal of Immunology
AllergyImmunology
2012English

CPSF3 Is a Promising Prognostic Biomarker and Predicts Recurrence of Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Biocompatibility Study Based on Differential Sequestration Kinetics of CD14+CD16+ Blood Monocyte Subsets With Different Dialyzers

Renal Failure
MedicineNephrologyCritical CareIntensive Care Medicine
2006English

Erratum To: CD14 Hi CD16+ Monocytes Phagocytose Antibody-Opsonised Plasmodium Falciparum Infected Erythrocytes More Efficiently Than Other Monocyte Subsets, and Require CD16 and Complement to Do So

BMC Medicine
Medicine
2015English

The CD4+/CD14+HLA-DRlo/neg Ratio as a Prognostic Biomarker in Cancer Patients

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2013English

Serum miR-26a as a Diagnostic and Prognostic Biomarker in Cholangiocarcinoma

Oncotarget
Oncology
2015English

Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer

Journal of Cancer
Oncology
2017English

CD16 on Dendritic Cells: A Biomarker of Metal Allergens

Translational Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy